Medline Inc. — fact timeline

Medline Inc. shareholders approved Ratification of the Selection of Ernst & Young LLP as Independent Auditor for Fiscal Year 2026 at the 2026-06-11 meeting.

“Stockholders ratified the selection of Ernst & Young LLP as the Company’s independent auditor for fiscal year 2026 as follows:”

Medline Inc. shareholders approved Advisory Vote on the Frequency of Votes on Executive Compensation at the 2026-06-11 meeting.

“Stockholders approved, on an advisory basis, a frequency of one year for future advisory votes on the Company’s executive compensation as follows:”

Medline Inc. shareholders approved Advisory Vote to Approve Executive Compensation at the 2026-06-11 meeting.

“Stockholders approved, on an advisory basis, the Company’s executive compensation as follows:”

Medline Inc. shareholders approved Election of 12 director nominees named in the proxy statement at the 2026-06-11 meeting.

“Stockholders elected each of the 12 nominees to serve as a director of the Company for a one-year term expiring at the Company’s 2027 Annual Meeting of Stockholders as follows:”

Medline Inc. entered into 2033 Refinancing Term Loan Facility with Not specified valued at Refinanced existing senior secured dollar-denominated term loan facility due 2030 with a new senior (effective 2026-05-28).

“Concurrently with the Notes offering, the Issuer refinanced its existing senior secured dollar-denominated term loan facility due 2030 (the “ 2030 Term Loan Facility ”) with a new senior secured dollar-denominated term loan facility in an aggregate principal amount of approximately $2,750.0 million (the “ 2033 Refinancing Term Loan Facility ” and, together with the existing revolving credit facility, the “ Senior Secured Credit Facilities ”).”

Medline Inc. entered into Indenture for 5.000% Senior Secured Notes due 2031 and 5.250% Senior Secured Notes due 2033 with Wilmington Trust, National Association valued at Issued $1,250.0 million aggregate principal amount of 5.000% senior secured notes due 2031 and $750. (effective 2026-05-28).

“On May 28, 2026, Medline Borrower, LP (the “ Issuer ”) and Medline Co-Issuer, Inc. (the “ Co-Issuer ” and, together with the Issuer, the “ Issuers ”), indirect subsidiaries of Medline Inc. (the “ Company ”), issued $1,250.0 million aggregate principal amount of 5.000% senior secured notes due 2031 (the “ 2031 Notes ”) and $750.0 million aggregate principal amount of 5.250% senior secured notes due 2033 (the “ 2033 Notes ” and, together with the 2031 notes, the “ Notes ”), under an Indenture, dated as of May 28, 2026 (the “ Indenture ”), among the Issuers, Medline Intermediate, LP (“ Holdings ”), the direct parent of the Issuer, the subsidiary guarantors party thereto and Wilmington Trust, National Association, as trustee (in such capacity, the “ Trustee ”), paying agent, transfer agent, registrar and notes collateral agent (in such capacity, the “ Notes Collateral Agent ”).”

Medline Inc. reported the three months ended March 28, 2026 results: revenue $7.4 billion, net income $239 million, EPS $0.16. Guidance raised.

“Net sales of $7.4 billion, an increase of 10.7% • Net income of $239 million, a decrease of 25.8%”

Medline Inc. entered into Information and Access Agreement with Company and entities affiliated with Hux Investment Pte. Ltd valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Information and Access Agreement, dated December 16, 2025, by and among the Company and entities affiliated with Hux Investment Pte. Ltd (the “ Information and Access Agreement ”).”

Medline Inc. entered into Director Nomination Agreement - Mills Family with Company and entities affiliated with the Mills Family valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Director Nomination Agreement, dated December 16, 2025, by and among the Company and entities affiliated with the Mills Family (the “ Mills Family Director Nomination Agreement ”);”

Medline Inc. entered into Director Nomination Agreement - H&F with Company and entities affiliated with Hellman & Friedman LLC valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Director Nomination Agreement, dated December 16, 2025, by and among the Company and entities affiliated with Hellman & Friedman LLC (the “ H&F Director Nomination Agreement ”);”

Medline Inc. entered into Director Nomination Agreement - Carlyle with Company and entities affiliated with The Carlyle Group Inc. valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Director Nomination Agreement, dated December 16, 2025, by and among the Company and entities affiliated with The Carlyle Group Inc. (the “ Carlyle Director Nomination Agreement ”);”

Medline Inc. entered into Director Nomination Agreement - Blackstone with Company and entities affiliated with Blackstone Inc. valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Director Nomination Agreement, dated December 16, 2025, by and among the Company and entities affiliated with Blackstone Inc. (the “ Blackstone Director Nomination Agreement ”);”

Medline Inc. entered into Registration Rights Agreement with Company and other persons valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Registration Rights Agreement, dated December 16, 2025, by and among the Company and each of the other persons from time to time party thereto (the “ Registration Rights Agreement ”);”

Medline Inc. entered into Exchange Agreement with Company, Medline Holdings and holders of common units valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Exchange Agreement, dated December 16, 2025, by and among the Company, Medline Holdings and holders of common units of Medline Holdings (“ Common Units ”) from time to time party thereto (the “ Exchange Agreement ”);”

Medline Inc. entered into Tax Receivable Agreement with Company and other persons valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“• the Tax Receivable Agreement, dated December 16, 2025, by and among the Company and each of the other persons from time to time party thereto (the “ Tax Receivable Agreement ”);”

Medline Inc. entered into Second Amended and Restated Limited Partnership Agreement of Medline Holdings, LP with Medline Holdings, LP and other parties valued at Entry into material definitive agreements in connection with IPO of Class A common stock (effective 2025-12-16).

“Item 1.01 Entry into a Material Definitive Agreement. In connection with the initial public offering (the “ Offering ” or the “ IPO ”) by Medline Inc. (the “ Company ”) of its Class A common stock, par value $0.0001 per share (the “ Class A Common Stock ”), described in the prospectus (the “ Prospectus ”), dated December 16, 2025, filed with the Securities and Exchange Commission pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the “ Securities Act ”), which is deemed to be part of the Registration Statement on Form S-1 (File No. 333-291112) (as amended, the “ Registration Statement ”), the following agreements were entered into: • the Second Amended and Restated Limited Partnership Agreement of Medline Holdings, LP (“ Medline Holdings ”), dated December 16, 2025, by and among the Company and the other parties thereto (the “ Medline Holdings Limited Partnership Agreement ”);”

Medline Inc.: Amended and Restated Bylaws became effective (effective 2025-12-16).

“On December 16, 2025, the Company’s Amended and Restated Certificate of Incorporation (the “ Charter ”), substantially in the form previously filed as Exhibit 3.1 to the Registration Statement, and the Company’s Amended and Restated Bylaws (the “ Bylaws ”), substantially in the form previously filed as Exhibit 3.2 to the Registration Statement, became effective.”

Medline Inc.: Amended and Restated Certificate of Incorporation became effective, setting authorized capital stock to 50B shares Class A common, 50B shares Class B common, and 5B shares preferred (effective 2025-12-16).

“On December 16, 2025, the Company’s Amended and Restated Certificate of Incorporation (the “ Charter ”), substantially in the form previously filed as Exhibit 3.1 to the Registration Statement, and the Company’s Amended and Restated Bylaws (the “ Bylaws ”), substantially in the form previously filed as Exhibit 3.2 to the Registration Statement, became effective.”